The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...

TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced microRNA Clinical Programs GLASGOW, Scotland, March 19, 2026 (GLOBE NEWSWIRE) -- Causeway ...

CKD was present in ~26% of adults with type 1 diabetes, yet only ~11% of those with CKD received CKM therapy, indicating ...

ClinCapture announces AI-powered clinical trial build tech that automates study configuration, and advances intelligent ...

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and ...

New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

BlueRock Therapeutics, a Bayer subsidiary developing stem cell treatments for Parkinson’s disease, has partnered with Rune ...

Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the most promising stocks under $100 to buy. On March 10, Kymera ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...